Inhibrx (INBX)

• Market cap: $385M
• 1 day: 0.08%
• 5 days: -3.76%
• 1 month: 11.4%
• 3 months: 82.12%
• 6 months: 90.75%
• Year to date: 74.36%
• 1 year: 54.41%
• 5 years: 112.55%
• 10 years: 112.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Employees: 161

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

1% less capital invested

Capital invested by funds: $151M [Q1] → $149M (-$2.01M) [Q2]

2.42% less ownership

Funds ownership: 74.52% [Q1] → 72.1% (-2.42%) [Q2]

5% less funds holding

Funds holding: 92 [Q1] → 87 (-5) [Q2]

35% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 34

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14